Mental Health Center Copenhagen, Bispebjerg
Copenhagen N, 2400, Denmark
Location status: Recruiting
NCT Number: NCT06752616
The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.
Interested in participating?
Request Info18 year–64 year
All sexes
Interventional
Phase 2 / Phase 3
Copenhagen N, 2400, Denmark
Location status: Recruiting
The initial treatment of acute agitation aims to reduce suffering, abort the immediate risk of harm to self or others, and prevent the use of coercive measures such a physical and mechanical restraint. With this research project, we aim to build the initial structure of a visionary platform design and to examine the efficacy, tolerability, and safety of two hitherto under-investigated compounds versus the current standard of care for acutely agitated patients when de-escalation techniques have failed. After obtaining the results of the initial phase, we plan to apply for future funding to maintain and expand the platform design with the addition of relevant experimental arms. The proposed platform design aims to anwer the question What is the best treatment for acutely agitated patients in inpatient psychiatric settings?
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs
Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs
Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
Time frame: 60 minutes
The Excited Component of the Positive and Negative Syndrome Scale (PEC) consists of 5 clinician-rated items associated with agitation from the Positive and Negative Syndrome Scale (PANSS). Scores range from 5 to 35. Higher is worse.
Time frame: 30, 60, 90, and 120 minutes
The earliest time where a statistically significant difference in agitation is apparent as measured by change from baseline PEC score (change from pre- to post-dose PEC score at 30, 60, 90, and 120 minutes)
Time frame: 30, 60, 90, and 120 minutes post-dose
Proportion tranquillized or asleep (measured as ≤4 on the BARS**) by 30, 60, 90, and 120 minutes post-dose
Time frame: 12 hours post-dose
Proportion physically restrained from administration to 12 hours post-dose
Time frame: 12 hours post-dose
Proportion mechanically restrained from administration to 12 hours post-dose
Time frame: 4-12 hours post-dose
Proportion given rescue medication 4-12 hours post-dose
Time frame: From 2 to 24 hrs post-dose when the participant is able to cooperate
Patient-reported satisfaction measured using 4 items from the Treatment Satisfaction Questionnaire for Medication II. Each item is answered on a 7-point Likert scale from 1 (extremely dissatisfied) to 7 (extremely satisfied). Score range is from 4 to 28. Higher is better.
Contact information is provided by the study sponsor or research team.
Lone Baandrup, MD, DMSc
CONTACT
Marie Vang Jensen, MD
CONTACT
Lone Baandrup
Other
Advancing the Quality of Treatment and Care for Acute Agitation in Emergency Psychiatry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06937229
Aberrant Motor Behavior in Dementia, Agitation
Chandler, Arizona, United States
View Trial DetailsNCT06052254
Aberrant Motor Behavior in Dementia, Agitation
Daytona Beach, Florida, United States
View Trial DetailsNCT06808984
Aberrant Motor Behavior in Dementia, Agitation
Homewood, Alabama, United States
View Trial DetailsNCT07568093
Aberrant Motor Behavior in Dementia, Agitation
Hanover, Lower Saxony, Germany
View Trial Details